NASDAQ$PSNL
Personalis Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported a decrease in revenue compared to the same quarter last year, but highlighted progress in biopharma opportunities and MRD test development.
Personalis reported a total revenue of $16.7 million for Q2 2023, an 8% decrease compared to Q2 2022. The company is focusing on expanding its biopharma opportunities and plans to launch its MRD test later this year.
- Announced collaboration with National Cancer Center Hospital East and Ono Pharmaceutical Co. Ltd for biomarker analysis.
- VA MVP exercised the first of four one-year renewal options under the September 2022 contract.
- Filed second patent infringement lawsuit against Foresight Diagnostics.
- Expects revenue growth to begin ramping later this year.
Headline financials
Revenue & EPS history
Personalis · Revenue · Quarterly
$16.7M
Revenue by segment
Personalis · $16.7M total across 4 segments · Q2 2023
- Enterprise sales$7.39M—44.2%
- Pharma tests and services$6.08M—36.4%
- Population sequencing$3M—18.0%
- Other$230K—1.4%
Forward guidance
Personalis expects total company revenue of approximately $17 million for the third quarter of 2023, with revenue from pharma tests, enterprise sales, and other customers of approximately $14 million, and revenue from population sequencing of approximately $3 million. For the full year of 2023, the company expects total company revenue in the range of $70 million to $72 million, with revenue from pharma tests, enterprise sales, and all other customers in the range of $61 million to $63 million, and revenue from population sequencing of approximately $9 million. Net loss is expected to be approximately $103 million, and cash usage is expected to be approximately $70 million.
Tailwinds
- Total company revenue of approximately $17 million for Q3 2023
- Revenue from pharma tests, enterprise sales, and other customers of approximately $14 million for Q3 2023
- Revenue from population sequencing of approximately $3 million for Q3 2023
- Total company revenue in the range of $70 million to $72 million for full year 2023
- Net loss of approximately $103 million for full year 2023
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+1.0%
Avg return
Earnings day
+1.5%
Avg return
5 days after
+1.5%
Avg return
30 days after
59%
16 / 27 earnings
Positive
+19.9%
Q1 2025
Best reaction
-23.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.2% | -0.7% | +76.6% | |
| Q4 2025 | +0.6% | -1.1% | -29.8% | |
| Q3 2025 | -12.3% | -1.1% | +9.5% | |
| Q1 2025 | +19.9% | +27.5% | +30.3% | |
| Q4 2024 | -2.4% | +5.9% | -14.6% | |
| Q3 2024 | -23.4% | -12.8% | -26.4% | |
| Q2 2024 | +7.2% | +34.7% | +67.8% | |
| Q1 2024 | +4.4% | -2.5% | -14.6% | |
| Q4 2023 | +3.3% | +16.0% | -0.7% | |
| Q3 2023 | +10.4% | -3.8% | +39.6% | |
| Q2 2023 | +4.7% | +7.9% | -17.9% | |
| Q1 2023 | +4.5% | +3.2% | -6.4% | |
| Q4 2022 | -7.2% | -5.3% | -18.2% | |
| Q3 2022 | -1.5% | -15.3% | +4.7% | |
| Q2 2022 | +10.6% | +11.1% | -21.4% | |
| Q1 2022 | -7.2% | -24.8% | -34.1% | |
| Q4 2021 | +12.2% | +11.0% | -14.4% | |
| Q3 2021 | +2.6% | -5.4% | -38.9% | |
| Q2 2021 | +10.2% | +4.1% | +12.4% | |
| Q1 2021 | -0.6% | -9.9% | -4.3% | |
| Q4 2020 | -11.1% | -10.8% | -36.3% | |
| Q3 2020 | +0.1% | -0.3% | +13.6% | |
| Q2 2020 | -2.4% | -3.7% | -4.7% | |
| Q1 2020 | +4.6% | +7.2% | +27.6% | |
| Q4 2019 | +17.5% | +27.5% | +52.8% | |
| Q3 2019 | +0.2% | -12.7% | +0.3% | |
| Q2 2019 | -15.6% | -6.2% | -11.6% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro